Author:
Masuda Kenta,Shiga Shuichi,Kawabata Hiroshi,Takaori-Kondo Akifumi,Ichiyama Satoshi,Kamikubo Yasuhiko
Funder
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Garcia-Manero G. Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90:831–41.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
3. Jonas BA, Greenberg PL. MDS prognostic scoring systems—past, present, and future. Best Pract. Res. Clin. Haematol. 2015;28:3–13.
4. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–85.
5. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.